论文部分内容阅读
目的探讨ADAM17、EMMPRIN在浸润性乳腺癌中的表达及相关性,证实ADAM17有可能成为乳腺癌靶向治疗的新靶标。方法采用免疫组化法检测ADAM17和EMMPRIN蛋白在浸润性乳腺癌、乳腺纤维腺瘤及正常乳腺组织中的表达情况。结果 ADAM17、EMMPRIN蛋白的免疫组化染色指数评分在浸润性乳腺癌为(4.57±0.66/8.50±0.73)、乳腺纤维腺瘤为(1.27±0.35/1.13±0.47)、正常乳腺组织为(0.17±0.04/0.15±0.08)。经单因素方差分析乳腺癌与乳腺纤维腺瘤及正常乳腺组织比较,ADAM17、EMMPRIN蛋白的表达差异具有统计学意义(P<0.05)。ADAM17及EMMPRIN表达强度与乳腺癌患者年龄、肿瘤大小无相关性(P>0.05);与腋窝淋巴结转移状况存在正相关性(P<0.05),且ADAM17和EMMPRIN表达呈正相关(r=0.068,P<0.05)。结论 ADAM17及EMMPRIN蛋白在乳腺癌组织中均存在高表达,且二者可能呈正相关性。ADAM17的异常表达或可作为临床诊断乳腺癌的一个新的辅助指标,并有可能成为一个新的乳腺癌靶向治疗的靶点。
Objective To investigate the expression and correlation of ADAM17 and EMMPRIN in invasive breast cancer and confirm that ADAM17 may be a new target of breast cancer targeted therapy. Methods Immunohistochemistry was used to detect the expression of ADAM17 and EMMPRIN protein in invasive breast cancer, breast fibroadenoma and normal breast tissue. Results The immunohistochemical staining scores of ADAM17 and EMMPRIN protein were (4.57 ± 0.66 / 8.50 ± 0.73) in invasive breast cancer and (1.27 ± 0.35 / 1.13 ± 0.47) in breast and 0.17 ± 0.04 / 0.15 ± 0.08). Compared with breast fibroadenoma and normal breast tissue, the expression of ADAM17 and EMMPRIN protein had statistical significance (P <0.05) by single factor analysis of variance. There was no significant correlation between the expression of ADAM17 and EMMPRIN and the age and tumor size of breast cancer (P> 0.05). There was a positive correlation between the expression of ADAM17 and EMMPRIN and the status of axillary lymph node metastasis (P <0.05) <0.05). Conclusion Both ADAM17 and EMMPRIN proteins are highly expressed in breast cancer tissues, and the two may be positively correlated. Aberrant expression of ADAM17 may serve as a new adjunct to clinical diagnosis of breast cancer and may serve as a new target for breast cancer targeted therapy.